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ABSTRACT
Objectives: In chronic kidney failure, there is impairment in the excretion of toxic non-volatile solutes, with consequent increase in the plasma 
concentrations of all metabolites derived mainly from protein metabolism, characterized by increased urea and creatinine, the prevalence and 
severity of anemia are related to the kidney disease stage and the relative deficiency or reduction in erythropoietin production is the main cause. This 
study aimed at checking the correlation between anemia and chronic kidney diseases in patients who underwent hemodialysis in Sabratha Hospital 
in the West of Libya.
Methods: This study was conducted on 60 patients (36 males and 24 females) with chronic renal failure from October 2015 to April 2016 and a group 
of 40 (20 males and 20 females) individuals as control.
Results and Conclusion: The results of the study concluded that there is a correlation between progression of chronic kidney diseases and reduction 
in hemoglobin, red blood cells count, hematocrit, and serum iron.
Keywords: Chronic kidney diseases, Chronic kidney disease, Anemia, Renal failure.
INTRODUCTION
The kidneys function as filters of the blood, removing waste products 
and controlling the balance of fluid and electrolytes. Filtration 
occurs via bundles of capillaries called glomeruli. A reduction in the 
glomerular filtration rate (GFR) to >60 mL/minutes/1.73 m2 indicates 
chronic kidney disease (CKD), as do structural or functional renal 
abnormalities, which may be present in people with normal GFR [1]. 
Cross-sectional estimates of the prevalence of CKD in the United States 
range from 1.5% to 15.6% [2].
Chronic kidney disease is a worldwide public health problem. Major 
outcomes of CKD include progression of CKD to end-stage renal 
disease, development of different complication due to impair kidney 
function, and increased risk for development of cardiovascular disease 
(CVD) [3]. One of the common complications of CKD is the anemia 
which is associated with increased risk for CVD, increased morbidity 
and mortality, especially in high-risk group [4]. The National Kidney 
Foundation (NKF) defines anemia in CKD as a hemoglobin (Hb) level 
>13.5 g/dl in men and 12.0 g/dl in women [5]. Anemia is common in 
diabetic patients with CKD [6]. It is estimated that one in five patients 
with diabetes and stage 3 CKD have anemia, and its severity worsens 
with more advanced stages of CKD and in those with proteinuria [7-9].
The prevalence and severity of anemia are related to the kidney 
disease stage and the relative deficiency or reduction in erythropoietin 
(EPO) production is the main cause, because the kidneys produce this 
hormone that stimulates red blood cell (RBC) production and when 
the patient develops CKD, he/she does not produce it in sufficient 
amounts. In addition of EPO deficiency, other situations may contribute 
to the occurrence of anemia in CKD, such as iron, folic acid and vitamin 
B12 deficiency; blood loss; hemolysis, hyperparathyroidism and 
inflammation, and these should be investigated before the introduction 
of EPO replacement therapy [10,11].
In chronic kidney failure, there is also impairment in the excretion 
of toxic non-volatile solutes, with a consequent increase in the 
plasma concentrations of all metabolites derived mainly from protein 
metabolism, characterized by increased urea and creatinine [12]. 
Creatinine dosage can be used as an aid in kidney function diagnosis, 
it is most useful and a more sensitive and specific indicator then 
urea [13]; however, other markers of renal function and renal damage 
have been investigated and may be introduced in clinical practice to 
assist in the diagnosis, monitoring, analysis, and prognosis of kidney 
disease progression [14].
Decline in GFR is associated with a step-wise increase in all-cause 
mortality at all levels of kidney function [15]. The vast majority of 
individuals with CKD will experience death due to cardiovascular 
causes rather than progress to end-stage renal disease or dialysis [16]. 
The high burden of CVD in CKD cohorts, and vice versa is a reflection of 
the fact that both disease processes share similar risk factors. Having 
one disease increases an individual’s risk of having the other; the 
combination of both is associated with a higher mortality than either 
disease alone [17-19]. This observation is consistent across a number 
of studies including subgroup analyses from the Antihypertensive 
and Lipid-Lowering Treatment to Prevent Heart Attack Trial [20]. 
CV end points, including myocardial infarction, stroke, need for 
revascularization, the presence of coronary artery disease and all forms 
of atherosclerotic vascular disease, were increased in study participants 
as GFR decreased. The presence or absence of anemia appears to add 
another layer of complexity to the relationship between CKD and CVD. 
Among individuals with CKD, at all levels of GFR, anemia portends a 
poor prognosis and is associated with increased mortality compared 
with those individuals with preserved Hb [21].
Anemia in CKD is associated with cognitive impairment, sleep 
disturbances, CKD progression, cardiovascular comorbidities, and 
higher mortality [22,23]. Direct healthcare costs are higher in CKD 
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patients with anemia than in those without [24], and quality of life 
issues (e.g., fatigue, reduced productivity) are common [22,23]. Anemia 
causes fatigue, reduced exercise capacity, reduced libido, and cognitive 
function, which ultimately have a negative impact on their quality of 
life [25,26] in addition to being related to heart failure, CVDs are the 
leading causes of mortality in CKD [27]. Thus, RBC indices, serum iron, 
transferrin, and ferritin saturation, among others, are tests that may 
be part of the clinical investigation and monitoring of patients with 
CKD [11]. Whereas anemia is one of the main consequences of CKD and 
when found, requires proper treatment and monitoring, checking the 
tests results can characterize the hematologic changes, iron behavior 
dynamics, as well as urea and creatinine concentrations and their 
possible relations with anemia in CKD patients on hemodialysis. Thus, 
this study aimed at checking the correlation between anemia and 
chronic kidney diseases in patients who underwent hemodialysis in 
Sabratha Hospital in the West of Libya.
METHODS
This study was conducted on 60 patients (36 males and 24 females) 
with chronic renal failure from October 2015 to April 2016 and a group 
of 40 (20 males and 20 females) individuals as control. Ethical approve 
and patients consent statement were taken from everyone, and the 
study was performed in Sabratha Hospital in the West of Libya. At first, 
all patients with proven chronic renal failure were included in the study. 
Patients with especial established disorders such as endocrinopathies, 
and hepatosplenomegaly and also patients with use of certain drugs 
such as heparin were excluded from the study. During the study, no 
patient had blood or blood components such as fresh frozen plasma and 
platelet transfusion. To eliminate effects of sex and age on a comparison 
between cases and control groups, age and sex were chosen in each 
pair of groups as similar as possible. Demographic and anthropometric 
data including age, sex, weight, height, body mass index, and blood 
pressure were measured for the participants. All of patients and normal 
participants were Libyans, above 18 years of age, and free from chronic 
degenerative diseases such as cancer or peritonitis.
A volume of 5 ml of blood was drawn by venipuncture. Collected blood 
sample was divided into two vials, that is, in ethylenediamine tetraacetic 
acid vial for hematological tests and plain vial for biochemical test. 
After clotting of blood in the plain vial, serum was separated, within 
an hour; by centrifugation at 3000-5000 g for 5 minutes. Serum was 
used for measurements of urea, creatinine, uric acid, and iron levels. 
Laboratory standard operation procedures were maintained for all 
laboratory analysis. Internal quality control sera, both normal and 
pathological, were also run for each lot of the test, for the validation of 
the results. Peripheral blood baseline parameters were measured using 
Sysmex KX 21 analyzer. Biochemical studies were performed using 
commercially available kits from Biomeriux (France), and serum levels 
of creatinine, urea, uric acid, and iron were quantified according to the 
manufacturer’s instructions.
Defining variables
Anemia was defined as Hb level <13.0 g/dL for men and 
<12.0 g/dL for women as per the World Health Organization guidelines. 
CKD was defined as reduced excretory function with an estimated GFR 
(eGFR)<60 ml/minutes/1.73 m2 as a marker of kidney dysfunction. 
Furthermore, CKD was defined and classified into five stages of CKD as 
per NKF guidelines. The formula of Cockcroft and Gault equation was 
used to calculate eGFR [28].
eGFR (in male)=(140-age [in years])×weight (in kg)/(72×serum 
creatinine [mg/dl]).
A companion equation for women, based on their 15% lower muscle 
mass (on average):
eGFR (in female)=(140-age [in years])×weight (in kg)×0.85/(72×serum 
creatinine [mg/dl]).
Statistical analysis
The data were analyzed using Excel 2010, and GraphPad Prism software 
version 5. Association between anemia and chronic kidney disease 
was tested by Pearson’s correlation test. Comparison of mean value of 
continuous data was tested by t-test and ANOVA test. p-value of <0.05 
(two-tailed) was used to establish statistical significance.
RESULTS
In this study, sixty patients (36 males, and 24 females) were classified 
according to their eGFR using of Cockcroft and Gault equation into three 
categories for each gender, stage III, stage IV, and stage V. In stage III, 
GFR from 30 to 59 ml/minutes, in stage IV, from 15 to 29 ml/minutes, 
and in stage V, the GFR is <15 ml/minutes. In our study, most of the 
patients within stage V limits, as illustrated in Fig. 1, 64% of males and 
50% of females. Stage IV patients are 25% of males and 33% of females, 
and the patients who within stage II limits are only 11% for males, and 
17% for females.
The patients also were classified according to their blood groups, we 
found that most of the patients were have blood Group O, 58% for males 
and 83.2% for females, and blood Group A were 27.7% for males and 
12.5% for females, the percentages of patients with blood Group B were 
11.1% for males and 4.1% for females, but there were no any female 
has blood Group AB, and there were only 2.8% of males who have this 
blood group (Fig. 2).
The kidney function tests which carried for these patients are, urea, 
creatinine, and uric acid in serum, and GFR was estimated for each 
patient using the formula of Cockcroft and Gault equation, by using 
the collected data of age, weight, and sex for each patient. These 
measured parameters, as illustrated in Table 1, showed that highly 
significant increase in serum creatinine in all stages of chronic renal 
Fig. 1: Distribution of chronic kidney disease patients according 
to stage of disease
Fig. 2: Distribution of chronic kidney disease patients according 
to blood groups
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failure in male patients by 273%, 610%, and 945% in stages III, IV, 
and V patients, respectively. The increase of serum creatinine levels in 
female patients were, 506%, 728%, and 1142% in stages III, IV, and V 
patients, respectively, as compared to control group. Serum urea levels 
were also increased significantly in all stages of chronic renal failure 
in male patients by 1037%, 1015%, and 913% in stage III, IV, and V 
patients, respectively, and the female patients showed highly significant 
elevations in serum urea by 658%, 966%, and 910% in stage III, IV, 
and V patients, respectively, as compared to healthy persons. The eGFR 
in all patient groups was decreased with highly significant degrees, as 
illustrated in Table 1. It decreased in male patients by −67%, −84%, 
and −90% in stage III, IV, and V patients, respectively. This parameter 
was reduced in female patients by −75%, −85%, and −90% in stage III, 
IV, and V patients, respectively, as compared to control persons. Serum 
uric acid was increased also by significant in male patient groups by 
71%, 44%, and 27% in stage III, IV, and V patients, respectively, whereas, 
its changes in female patients were 40%, 50%, and 31% in stage III, IV, 
and V patients as compared to healthy control group (Table 1).
Measurements for peripheral blood were carried out for RBCs, white 
blood cells (WBCs), and platelets count, Hb concentration, hematocrit, 
and serum iron were also measured, mean corpuscular hemoglobin 
(MCH), MCH concentration (MCHC) and mean corpuscular volume 
(MCV) were calculated. The hematological data were tabulated in 
Table 2 which showed significant changes compared to healthy control 
group, these changes were appeared as decrease in Hb concentrations 
in male patients by −17%, −18%, and −30% in stage III, IV, and V 
patients, whereas the changes in this parameter in female patients are 
−11%, −20%, and −26% in stage III, IV, and V patients as compared 
to control. RBCs count was also decreased in all patient groups with 
statistically significant degrees, as illustrated in Table 2. The changes in 
RBCs count in male patients are −34%, −38% and −38% in stage III, IV, 
and V patients, respectively, whereas, these changes in females are 
−21%, −28%, and −28% for stage III, IV, and V, respectively as compared 
to healthy women. Hematocrit percentage were also reduced in all 
patient groups by −37%, −46%, and −38% in male patient groups 
of stages III, IV, and V, respectively, whereas, in female patients the 
percentages of reduction in this parameter are −30%, −36%, and −32% 
in stage III, IV, and V patients.
Serum iron levels were also reduced by −34% and −42% in stage IV 
and V patients respectively, but there is a significant change in stage II 
male patients. In female, the degrees of reduction in serum iron are 
−29% and −41% in stage IV and V patients. Platelets count was also 
decreased in patient groups by −38% and −26% in stage V male and 
female patients, respectively.
The data in Table 3 show the correlation between the changes in kidney 
function tests and hematological parameters. This correlation was 
appeared between serum creatinine and Hb, RBCs count, hematocrit, 
MCH, MCHC, and serum iron, on the other hand, no correlation between 
creatinine and WBCs or platelets count. In this table also, the correlation 
between serum urea concentration and blood data were illustrated. These 
data showed a correlation between serum urea and Hb and RBCs count 
but no correlation between urea and other hematological data. eGFR also 
showed correlation with Hb, RBCs count, MCHC, and serum iron.
DISCUSSION
Chronic kidney disease is a major public health problem and a major 
cause of morbidity and mortality worldwide. CKD is diagnosed on the 
basis of the presence of markers of kidney damage and kidney function. 
This study was carried out to assess the hematological profile in CKD 
including the Hb, RBCs count, WBCs count, platelets count, hematocrit, 
MCH, MCHC, MCV, and serum iron and their correlation with renal 
function tests.
Anemia in CKD is typically normocytic, normochromic, and 
hypoproliferative. The demonstration of a circulating factor responsible 
for stimulating erythropoiesis and the kidney as the main source of EPO 
in the 1950s [29,30] engendered the hypothesis that EPO deficiency is a 
predominant cause of anemia in CKD.
Numerous studies suggest that circulating uremic-induced inhibitors of 
erythropoiesis contribute to the anemia, shortened RBC survival also 
contributes, as demonstrated by radioisotope labeling studies. Although 
the etiology is not entirely clear, metabolic, and mechanical factors have 
been proposed [31,32]. In this study, reduction in Hb, RBCs count, and 
hematocrit is in accordance with the study of Poudel et al. [33], Bueno 
and Frizzo, [34] and de Francisco et al. [35].
Iron deficiency in the general population is a common cause of 
anemia and is prevalent in patients with diabetes and CKD. In these 
same patients, dietary deficiency, low intestinal absorption, and 
gastrointestinal bleeding may result in absolute iron-deficiency anemia. 
Recent analyses of the National Health and Nutrition Examination Survey 
IV suggest that up to 50% of patients with CKD stages 2-5 have absolute 
or relative (functional) iron deficiency [36]. In CKD, both absolute and 
relative iron deficiency are common. Absolute iron deficiency is defined 
as a depletion of tissue iron stores evidenced by a serum ferritin level 
>100 ng/ml or a transferrin saturation of >20%. Functional iron 
deficiency anemia is adequate tissue iron defined as a serum ferritin 
level >100 ng/ml and a reduction in iron saturation. The latter is more 
common and is strongly associated with upregulation of inflammatory 
cytokines and impaired tissue responsiveness to EPO, which can inhibit 
iron transport from tissue stores to erythroblasts [37]. Increased levels 
of inflammatory cytokines such as interleukin-6 enhance production 
and secretion of hepcidin. Hepcidin is the main hormone responsible 
for maintaining systemic iron homeostasis, produced by the liver and 
secreted into circulation, hepcidin binds and induces degradation of the 
iron exporter, ferroportin, on duodenal enterocytes, reticuloendothelial 
macrophages, and hepatocytes to inhibit iron entry into the plasma. 
Inflammatory cytokines directly induce hepcidin transcription, 
presumably as a mechanism to sequester iron from invading pathogens, 
leading to the iron sequestration, hypoferremia, and anemia that are 
hallmarks of many chronic diseases including CKD. Numerous studies 
show that hepcidin is elevated in CKD patients. Mechanisms suggested 
Table 1: Kidney function tests in healthy persons and chronic kidney disease patients
Patient groups Gender Mean±SD
Urea (mg/dl) Creatinine (mg/dl) eGFR (ml/minutes) Uric acid (mg/dl) 
Control Male 25.8±9.05 0.93±0.11 120±15.85 4.8±0.58
Female 27.3±10.2 0.75±0.09 121±13.33 4.9±0.61
Stage III Male 293.5**±227.0 3.135**±0.5162 40.04**±6.336 8.225**±1.096
Female 207.0**±104.7 4.550**±1.485 29.79**±8.167 6.750*±3.182
Stage IV Male 287.7**±78.58 6.610**±1.259 18.28**±1.875 6.920*±1.963
Female 291.1**±81.32 6.213**±0.9326 18.12**±2.507 7.213**±2.319
Stage V Male 261.5**±45.59 9.720**±2.642 11.46**±2.477 6.130*±1.616
Female 275.8**±68.58 9.320**±2.795 11.59**±2.566 6.302*±2.418
*Significant difference compared to control group (p<0.05). **Highly significant difference compared to control group (p<0.01). SD: Standard deviation, eGFR: Estimated 
glomerular filtration rate
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to account for this are increased expression by inflammatory cytokines 
and reduced renal clearance [38].
Based on its ability to donate and accept electrons, iron is essential for 
many important biologic reactions, including oxygen transport, cellular 
respiration, and DNA synthesis. However, this same property makes 
excess iron toxic by generating free radicals that can damage or destroy 
cells. Systemic and cellular iron levels must, therefore, be tightly 
regulated. The majority of iron (20-25 mg) is provided by recycling 
from senescent RBCs, which are phagocytosed by reticuloendothelial 
macrophages to store iron until it is needed, with lesser amounts 
provided by dietary absorption in the duodenum (1-2 mg) and release 
from liver stores. Plasma iron, which circulates bound to transferrin, is 
relatively limited at 3 mg, and therefore must be turned over several 
times to meet the daily requirements for erythropoiesis. With no 
regulated mechanism for iron removal, typical iron losses are 1-2 mg 
daily, mainly from intestinal and skin cell shedding and menstruation 
in reproductive-age women. Systemic iron balance is, therefore, 
maintained by regulating dietary iron absorption and iron release from 
storage sites in the liver and reticuloendothelial macrophages [39]. In 
the current study, serum iron level was reduced significantly in stage V 
patients of CKD, and this in accordance with the previous studies of 
Mezzano et al. [37] and Babitt and Lin [39].
Both deficiency and hyporesponsiveness to EPO contribute to 
anemia in diabetic patients with CKD. The cause of EPO deficiency in 
these patients is thought to be reduced renal mass with consequent 
depletion of the hormone. Hyporesponsiveness is defined clinically as a 
requirement for high doses of EPO to raise blood Hb level in the absence 
of iron deficiency. It is believed to represent impaired antiapoptotic 
action of EPO on proerythroblasts. Possible causes of this EPO 
hyporesponsiveness include systemic inflammation and microvascular 
damage in the bone marrow [9]. However, some studies suggest that 
other factors (i.e., autonomic failure) may play a role in impaired EPO 
production or secretion by failing kidneys.
Hassoon et al.,[40] found that the percentage of the renal failure patients 
that carried O blood group was the highest (55%) followed by the B 
blood (25%), A blood group (12.5%) and AB blood group (9.4%) [40]. 
In another study, the occurrences of renal failure in Group O were 
69.5%, and Group B was 42%, whereas AB was zero and 69% was for A 
blood group [41]. In our study, about 65% of CDK patients with blood 
Group O, which in accordance with the previous studies. Dorgalaleh 
et al., [42] reported that platelet count was statistically significant 
decreased and mild thrombocytopenia in chronic renal failure patients. 
Although the mean platelet count did not show that our patients have 
not in a potential bleeding risk thrombocytopenia was an important 
risk factor for the occurrence of bleeding among a minority of our study 
patients. Furthermore, authors were found a mild thrombocytopenia 
among chronic renal failure patients.
CONCLUSION
This study concluded that there is a correlation between progression of 
chronic kidney diseases and reduction in Hb, RBCs count, hematocrit, 
and serum iron.
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